Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

21

Revenue 2017

41

Revenue 2017

Xarelto

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xarelto was produced by Bayer and Johnson & Johnson.

Pharma sales help Bayer escape the worst from a bumpy 2017

Pharma sales help Bayer escape the worst from a bumpy 2017

Together they brought in just over 6.5bn, although Xarelto and Eylea accounted for over 80% of the total. ... Among them were a 7, 000 patient study of Xarelto in secondary stroke, a combination trial of Eylea and a drug-device combination for pneumonia.

Bad news for Portola as CHMP considers Factor Xa drugs

Bad news for Portola as CHMP considers Factor Xa drugs Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

The good, the bad and the ugly

The good, the bad and the ugly Canada. Nonetheless, new rival innovation in the anticoagulant market is already presenting challenges for Xarelto. ... This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.

Joerg Moeller to head Bayer R&D after operational shake-up

Joerg Moeller to head Bayer R&D after operational shake-up It will also highlight its plans to expand the use of novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) into coronary and peripheral artery disease, along with new-generation anticoagulants in mid-phase

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...
How to measure health behaviour change programmes
Creating health intervention programmes based on outcomes rather than processes provides new ways of measuring health behaviour change....
Recent approval for your brand from NICE or SMC? Time to rethink your market access
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions....

Infographics